Read More

Regeneron’s and Sanofi’s Dupixent SmPC Updated With Long-term Data Reinforcing Well-established Safety Profile in Adults With Moderate-to-severe Atopic Dermatitis

Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use.

REGN